Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon was selected as a constituent stocks of the STAR 50 Index

Page View:
On February 25, the Shanghai Stock Exchange announced that they decided to adjust the sample of the STAR 50 Index, which will take effect after the market closes on March 11, 2022.

Shanghai Medicilon Inc. (Medicilon) was selected as a constituent stock of the "STAR 50" Index.

stocks of the STAR 50 Index.jpg

The Sci-Tech Innovation Board was launched on July 22, 2019. The board selected a group of high-tech companies that conform to the national development strategy, possess key core technologies, have high market recognition, and have strong scientific and technological research and development capabilities.  The selection of "STAR 50" can be described as the best of the best, showing three characteristics: sufficient representation, distinctive industry characteristics, and outstanding scientific and technological attributes.
Medicilon has achieved strong and stable growth since it was listed on the STAR Market on November 5, 2019 and became the first CRO company listed on the STAR Market.  In 2020, the income for Medicilon was RMB 666 million, an increase of 48.19%, and the net profit was RMB 129 million, an increase of 94.35%.  In 2021, the income for Medicilon was RMB 1.167 billion , an increase of 75.27%; the net profit was RMB 282 million, an increase of 117.93%.
Throughout the development of Medicilon, technological innovation runs through it, which is the driving force for the rapid growth of Medicilon.  In the past 18 years, Medicilon has actively built a number of innovations and service platforms such as protein degradation technology (PROTAC), small molecule drug development platform for kinase inhibitors, tumor immune efficacy evaluation, inhalation and ophthalmic drug evaluation, and AI-assisted new drug design platform.  In 2022, Medicilon plans to launch more advanced R&D service platforms such as nucleic acid drug bioanalysis platform, antibody drug discovery platform, and stroke pharmacodynamic model platform to provide more possibilities for empowering innovative drug research and development.
Profession creates value, service creates brand, Medicilon has been recognized by the industry and the market for its high-growth performance, high-investment technological innovation, and high-quality R&D services.  Medicilon has won a number of industry awards in succession such as "2021 Most Valuable Sci-Tech Innovation Board Biomedical Listed Company", "Science and Technology Innovation Golden Horse Outstanding Company Award", "Top 50 Listed Companies in Growth" and "Golden Bull Science and Technology Innovation Award". Medicilon was added to the MSCI China A-Share Index.
The entry into the "STAR 50" index list further shows that Medicilon's performance on the Sci-Tech Innovation Board has been fully recognized by the market.  As a "leader" in China's CRO industry, Medicilon will continue to adhere to the concept of "innovation-driven, quality first", to develop key core technologies, to help the forward-looking research and development of innovative drugs, and to contribute to the health of all mankind worldwide.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  Medicilon grows together with the clients and delivers the new drug research and development services to more than 900 clients globally.  Medicilon is proud to contribute to human health in the globe.

Contact Us:

Related Reading:

Relevant newsRelevant news